The authors reported that among 86 cancer patients mainly treated with LMWHs, DOACs, or LMWHs plus DOACs, there was a higher overall bleeding rate in patients anticoagulated and concomitant use of VEGFR-TKIs compared to patients who were receiving only anticoagulants (HR 2.45 [1.28-1.69]). The gene discussed is KDR; the disease is cancer.